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ABSTRACT
Nowadays, vesicles have become the carrier of choice in drug delivery. 
Vesicular drug delivery reduces the cost of therapy by improved bioavailability 
of medication, especially in case of poorly soluble drugs. They can incorporate 
both hydrophilic and lipophilic drugs. Proniosomes are one of the important 
novel drug delivery carriers of various drug molecules. The design of the 
present investigation was to prepare and develop Metronidazole Benzoate 
loaded proniosomes with different ratios of cholesterol and non-ionic 
surfactants to achieve prolonged release of drug on topical administration. A 
total of fourteen formulations were prepared by slurry method and evaluated 
for angle of repose, drug content, particle size, hydration rate, encapsulation 
efficiency, in-vitro release studies& ex-vivo drug permeation studies. The 
optimized formulation of proniosome was incorporated into transdermal patch 
and was subjected to various evaluation studies. The in-vitro diffusion and 
kinetic study of the patch showed a release of 80.71% over 12hrs and fitted 
into zero order and non-fickian diffusion mechanism. It could be concluded 
that the formulationF12 having surfactant: cholesterol concentration as 1:1 was 
the best formulation. The SEM image as well as the FT-IR spectrum of the 
optimized formulation was taken.
Keywords: Metronidazole benzoate, Proniosome, Slurry method, In vitro
drug release, Ex vivo permeation study, SEM.
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                                      INTRODUCTION 
The skin is the single largest organ of the body. Skin serves as a barrier for the drugs to pass
through it. Percutaneous absorption involves the passage of the drug molecule from the skin
surface into the stratum corneum under the influence of the concentration gradient and its
subsequent  diffusion through the stratum corneum and underlying epidermis,  through the
dermis and into the blood circulation. The resistance provided by the skin is the major rate
limiting step in the percutaneous absorption.1
Various techniques have been employed to weaken the skin barrier and deliver the drug into
the body through the intact skin. Some of the techniques include iontophoresis, sonophoresis,
electroporation, use of chemical enhancers and microneedles. These methods are not used
now because of limited efficacy, skin irritation, complexity in usage and high cost. Due to
this  many  elastic  lipid  systems  like  niosomes,  liposomes  ,transfersomes,  niosomes  and
proniosomes were developed in order to penetrate deeply and easily into skin. These vesicles
squeeze themselves through the pores of the stratum corneum due to their highly flexible
membrane.2
VESICULAR DRUG DELIVERY SYSTEM 3
Vesicular drug delivery systems have gained a lot of interest as a carrier for advance drug
delivery. Encapsulation of the drug in carrier structures is one such system, which delays the
drug release and reduces the toxicity by selective uptake. The drug delivery systems using
colloidal particulate carriers such as liposomes or niosomes have proved distinct advantages
over conventional dosage forms because they can act as drug reservoir and can carry both
hydrophilic and hydrophobic drugs. The vesicles dispersed in aqueous systems may suffer
from some problems like degradation by hydrolysis or oxidation, sedimentation, aggregation
or  fusion  of  liposomes  during  storage.  Two  novel  approaches  adopted  to  avoid  these
problems  were  to  develop  the  proliposomes  and  to  develop  niosomes  using  non-ionic
surfactants  alternative  to  phospholipids  in  preparing  vesicles.  Though  proliposomes  are
advanced over conventional liposomes some physical instability still persist, so a vacuum or
nitrogen atmosphere is optional during preparation and storage to prevent the oxidation of
phospholipids. In later approach, niosomes exhibit good chemical stability during storage but
the  aqueous  suspension of  niosomes exhibit  physical  stability problems like  aggregation,
fusion,  leaking  of  entrapped  drugs  or  hydrolysis  of  encapsulated  drugs  etc.  The  latest
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approach  in  the  field  of  vesicular  delivery  is  to  combine  the  two  previously  mentioned
techniques by extending the pro-vesicular approach to niosomes through the formation of
“proniosomes” which are converted to niosomes.
TYPES OF VESICULAR DRUG DELIVERY SYSTEM 4
1. Liposomes
2. Virosomes
3. Niosomes
4. Proniosomes
5. Transfersomes
6. Proteasomes
7. Sphingosomes 
8. Ethosomes
LIPOSOME 5
They are artificially prepared vesicles composed of lipid bilayer. They can be prepared by
disrupting the biological membrane.  They are composed of natural phospholipids and may
also contain lipid chains with surfactant properties.
VIROSOME4
They consists of uni lamellar phospholipid  membrane which is either a mono or bi layer
vesicle incorporating virus derived proteins to allow virosomes to fuse with target cells.
NIOSOME4
They are non- ionic surfactant based liposome. Niosomes are mostly formed by cholesterol
incorporation. They are structurally similar to liposomes.
TRANSFERSOME4
A transfersome carrier is an artificial vesicle designed to be such as a cell vesicle or a cell
engage in exocytosis & thus suitable for controlled & potentially targeted drug delivery.
PROTEASOME4
They are cytoplasmic organelles responsible for degrading endogenous proteins because of
the presence of ubiquitin conjugated to the targeted protein’s lysine residue.
SPHINGOSOME6
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They are bilayered vesicles in which an aqueous volume is entirely enclosed by lipid bi- layer
membrane mainly composed of natural or synthetic sphingolipid.
ARCHAESOME4
These are liposomes made from polar ether lipids of Archaea.
ETHOSOME 7
They  are  modified  forms  of  liposomes  which  have  high  ethanol  content.  They  are
flexible,malleable vesicles adapted for enhanced delivery of active agents.
PRONIOSOME8
Proniosomes  are  dry, free  flowing,  granular  product  that  could  be  hydrated  immediately
before use by agitation in aqueous media to form the niosomal suspension.
                      
Figure1: Schematic diagram of proniosome
ADVANTAGES OF PRONIOSOMES 3
 The  problems  of  physical  stability  like  fusion,  aggregation,  sedimentation,
&leakage on storage can be reduced.
 Hydrolysis of encapsulated drug which limits the shelf life can be avoided.
 Since it’s a dry formulation provide convenience in storage and transportation.
 Provides drug delivery with improved bioavailability &reduced side effects.
 Both hydrophilic and hydrophobic drugs can be entrapped.
 Shows controlled and sustained release of drugs due to depot formation.
 Biodegradable, biocompatible & non-immunogenic to the body.       
INTERACTION BETWEEN PRONIOSOME AND SKIN 9
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There is a direct contact of the proniosomal formulation with the skin after it is applied. Since
the  proniosomes  are  made of  non-ionic  surfactants,  it  is  important  to  study the  possible
interactions between the non-ionic surfactants and the skin.  The non-ionic surfactants are
amphipathic molecules consisting of hydrophobic (alkylated phenol derivatives, fatty acids,
long chain linear alcohol etc) & a hydrophilic part (ethylene oxide chains of variable length).
Skin consists of a range of bio active materials like membrane phospholipids, proteins, amino
acids, peptides etc.
  Surfactants are known to increase the permeability of vesicles and phospholipid membranes,
causing low molecular mass compounds to leak. The non-ionic surfactants are included in the
pharmaceutical formulations to increase their stability, solubility & permeation. 
FACTORS AFFECTING NATURE OF PRONIOSOMES
 Hydration temperature
 Choice of main surfactant
 Nature of drug
 Nature of membrane additives
 Size reduction techniques
 Addition of kinetic energy
MECHANISM OF DRUG PERMEATION FROM VESICLES THROUGH SKIN19
The following types of vesicle-skin interactions are observed during  in-vitro studies using
human skin.
1. Absorption & fusion of vesicles onto skin surface leads to increase in thermodynamic
activity  gradient  of  the  drug  at  the  interface,  which  acts  as  a  driving  force  for
absorption of lipophilic drugs across the stratum corneum .
2. Modification in  the structure of the stratum corneum is also a  type of interaction
which involves the ultra structural changes in the intracellular lipid region of the skin
& its deeper layers which is revealed by Freeze Fracture Electron Microscopy 
(FFEM) & Small angle X- ray scattering (SAXS).  
3. Bilayer present in the niosomes act as rate limiting barrier for drugs.
4. Proniosomes  contain  both  non-ionic  surfactant  &  phospholipids,  both  can  act  as
penetration enhancer & are useful in increasing penetrability of many drugs.
5. The  penetration  enhancer  effect  of  vesicles  to  reduce  stratum  corneum  barrier
properties.
MECHANISM OF VESICLE FORMATION IN PRONIOSOMES19
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Non-ionic surfactants have the ability to form bilayer vesicles which depends on the HLB of
surfactant  &  also  on  critical  packing  parameter.  CPP can  be  defined  as  the  relationship
between  structure  of  surfactant  including  size  of  hydrophilic  head  group  &  length  of
hydrophobic alkyl chain in the ability to form vesicles is described as 
                                                     CPP= u/lca                                       (1)
Where, u= the hydrophilic group volume 
            lc =critical hydrophobic group length
            a= area of hydrophilic head group
When the value of CPP is between 0.5 to 1, then the surfactant is likely to form vesicles. CPP
below  0.5(indicates  that  there  is  high  contribution  from hydrophilic  head  groups)  gives
spherical micelles & value of CPP above 1 (indicates that there is high contribution from the
hydrophobic group) gives inverted micelles which on later stage gives precipitation. Spans
are most widely used in proniosomal preparation. 
All grades of span have same head group but are differentiated on basis of alkyl chain. The
entrapment efficiency increases as the alkyl chain length increases.
Span60 (C18)  > Span40 (C16) > Span20 (C12) > Span80 (C18).
Span 60 &80 have same head group but there is difference in the alkyl chain of span80 which
is unsaturated.
The low entrapment efficiency of span80 may be due to introduction of double bond to its
paraffin chain. Cholesterol also provides stability to the bilayer membrane by increasing gel
liquid transition temperature of vesicles &also attributes to high HLB value & small CPP.
CATEGORIES OF PRONIOSOMES
 Dry Granular type of proniosome
         *Sorbitol based proniosomes
         *Maltodextrin based proniosomes
 Liquid crystalline proniosome
DRY GRANULAR PRONIOSOME 10
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Dry granular  type  of  proniosomes  involves  the  coating  of  water-soluble  carrier  such  as
sorbitol and maltodextrin with surfactant. The result of coating process is a dry formulation in
which each water-soluble particle is covered with thin film of surfactant. It is essential to
prepare vesicles at a temperature above the transition temperature of the non-ionic surfactant
being used in the formulation. These are further categorized as follows
 Sorbitol based proniosome 
Sorbitol based proniosomes is a dry formulation that involves sorbitol as the carrier, which is
further coated with non-ionic surfactant and is used as niosomes within minutes by addition
of hot water followed by agitation. They are normally made by spraying surfactant mixture
prepared in organic solvent onto the sorbitol powder and then evaporating the solvent. Since
the sorbitol carrier is soluble in organic solvent, the process is required to be repeated till the
desired surfactant coating has been achieved. The surfactant coating on the carrier is very thin
and hydration of this coating allows multilamellar vesicles to form as the carrier dissolves.
 Maltodextrin based proniosome 11
Maltodextrin  is  used  as  the  carrier. The principal  advantage  with  this  formulation  is  the
amount of carrier required to support the surfactant could be easily adjusted and proniosomes
with very high mass ratios of surfactant to carrier could be prepared.
LIQUID CRYSTALLINE PRONIOSOME
When the surfactant molecules are in contact with water, the lipohilic chains of surfactants
get transformed into a disordered liquid state called lytorophic liquid crystalline state also
called as neat phase. This transformation occurs by increasing the temperature at the kraft
point , addition of solvent or use of both the temperature & solvent.
  Neat phase or lamellar phase contains bilayer arranged in sheets over one another within the
intervening  aqueous  layer.  These  liquid  crystalline  proniosomes  act  as  a  reservoir  for
transdermal delivery of drug.
PRONIOSOMES AS DRUG CARRIERS8
The proniosomes are promising drug carriers as they possess greater chemical stability and
lack of many disadvantages associated with liposomes.  Additional merit  is its non –toxic
nature due to the use of non-ionic surfactants in its preparation. It does not require special
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conditions  and  precautions  for  formulation  and  preparation.  They  are  dry  free  flowing
product  which  makes  them more  stable  during  sterilisation  and  storage  &  also  ease  of
transfer, distribution and measuring make them a pronouncing versatile delivery system.
COMPONENTS OF PRONIOSOMES12
Surfactants
Surfactants  are  surface  active  agents  usually  organic  compounds  that  are  amphiphilic  in
nature  i.e  they  have  have  both  hydrophobic  &  hydrophilic  groups.  They  function  as
solubilizer, wetting agents,emulsifier & permeability enhancer. Only non-ionic surfactans are
used for the preparation of proniosomes.
e.g :* Alkyl ethers & alkyl glyceryl ethers- Polyoxyethelene 4 lauryl ether
                                                                     Polyoxyethelene cetyl ethers
                                                                     Polyoxyethelene stearyl ethers 
      *Sorbitan fatty acid esters                    -Span20,40,60,80
      *Polyoxyethelene  fatty acid esters      -Tween 20,40,60,80
Carrier material
The carrier which is non- toxic, free flowing, poor solubility in the solvent are used for the
preparation of proniosome & good aqueous solubility for hydration.
E.g:  Maltodextrin,  sorbitol,  mannitol,  spray  dried  lactose,  glucose  monohydrate,  lactose
monohydrate, sucrose stearate.
Membrane stabilizer
Cholesterol &lecithin are mainly used as membrane stabilizer. They influence the stability
&permeability of the vesicles. Steroids are components of cell membrane, they bring about
significant changes in the bilayer stability, fluidity & permeability. Cholesterol is a naturally
occurring  steroid  used  as  membrane  additive.  It  stabilises  the  system  by  means  of
electrostatic effects &also by prevention formation of the aggregates. It also leads to change
of gel state to liquid state in niosomal system.
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Phosphatidylcholine is a major constituent of lecithin. It has low solubility in water & can
form liposomes, bilayer sheets, micelles structures depending on hydration & temperature.
Depending on the source, there are egg lecithin & soya lecithin. The vesicles composed of
soya lecithin are larger in size then the one formed from egg lecithin, due to the difference in
intrinsic composition.
Solvent & aqueous phase
Alcohol used in proniosome has a great effect on vesicle size & drug permeation rate. The
size  of  the  vesicles  formed  from  different  alcohol  is  different  and  are  in  the  order:
ethanol>propanol>butanol>isopropanol.  Ethanol forms the largest sized vesicles due to its
greater solubility in water. Ispropanol forms vesicles of smallest  size due to its  branched
chain. Phosphate buffer pH7.4, 0.1% glycerol, hot water is used as the aqueous phase in the
preparation of proniosomes.
PREPARATION OF PRONIOSOMES
There are 3 methods of preparation:
 SLURRY METHOD9
The carrier was taken in RBF and the entire volume of surfactant dissolved in the organic
solvent was added to form slurry. The flask was then attached to the rotary evaporator &
vacuum was applied until a dry free flowing powder was obtained. The flask was removed
from the evaporator and kept under vacuum overnight. The obtained proniosomal powder
was stored in sealed container at4ºC. 
 COASERVATION PHASE SEPARATION METHOD12
Weighed amounts of surfactant, lipid & drug were taken in a clean dry wide mouthed glass
vial &0.5ml alcohol was added to it. All the ingredients were mixed well after warming. The
vial was closed with a lid to prevent the loss of solvent. The surfactant mixture was dissolved
completely by warming it over a water bath at 60-70ºC. Then the aqueous phase was added &
warmed on water  bath till  a  clear  solution was formed which was then converted into a
proniosomal gel.
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 SLOW SPRAY COATING METHOD9
This method involves preparation of proniosomes by spraying surfactant in organic solvent
onto the carrier  (sorbitol)  & then evaporating the solvent.  Because the sorbitol  carrier  is
soluble in the organic solvent, it is necessary to repeat the process until the desired surfactant
loading has been achieved. The surfactant coating on the carrier is very thin and hydration of
this coating allows multilamellar vesicles to be formed as the carrier dissolves. The resulting
niosomes  are  very  similar  to  those  produced  by  conventional  methods  and  the  size
distribution is more uniform. 
DRUG OF CHOICE3
The drug selection should be based on the following assumptions:
 Should have low aqueous solubility.
 Suitable for controlled drug delivery.
 Higher adverse drug reactions.
 Short half-life.
TRANSDERMAL DRUG DELIVERY20
Transdermal drug delivery is defined as self-contained, discrete dosage form which when
applied to unbroken skin , delivers the drug through the skin in a controlled manner to the
systemic  circulation.  The  transdermal  patch  uses  a  polymer  to  control  the  rate  of  drug
delivery from the reservoir through the skin & into the blood stream. The approach of TDDS
is more significant in case of chronic disease like HTN, which require prolonged period of
dosing to maintain therapeutic drug concentration.
ADVANTAGES OF TDDS21
1. Avoids FPM of  drugs
2. Reduction of fluctuations in plasma levels.
3. Reduced plasma drug concentration with decreased side effects.
4. Reduction of dosing frequency & enhancement of patient compliance.
5. Maintains the plasma drug concentration of potent drugs.
6. Termination of therapy is easy at any point of time.
7. Site specific delivery of drug is possible.
8. Self- administration is possible.
LIMITATIONS OF TDDS
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a. Not suitable for those which require more than 10mg/day.
b. Patients  develop  contact  dermatitis  at  the  site  of  application  for  one  or  more
components, necessitating discontinuation.
c. Only moderately potent drugs can be incorporated.
d. The function of the skin changes from one site to another in the same individual &
from individual to individual & with age.
Conditions for drug permeation
Hydration: Hydrated skin is more permeable.
Broken  or  irritated  skin:  Drugs  can  more  easily  bypass  the  stratum  corneum,  increases
permeability.
Temperature: Warmer skin is more permeable.
Sunburn: Initially skin is less permeable, after peeling it becomes more permeable.
Psoriasis:  Regions exhibit increased or decreased permeability.
Skin as a Site for Drug Infusion25,26
 The skin of an average adult body covers a surface area of approximately two square meters
and  receives  about  one-third  of  the  blood  circulating  through  the  body.  The  skin  is  a
multilayered organ composed of many histological layers. It is generally described in terms
of three major tissue layers: the epidermis, the dermis, and the hypodermis. Microscopically,
the epidermis is further divided into five anatomical layers with stratum corneum forming the
outer most layer of the epidermis, exposing to the external environment.  
An average human skin surface is known to contain, on the average, 40-70 hair follicles and
200-250 sweat  ducts on each cm2 of  skin area.  These skin appendages  however  actually
occupy grossly, only 0.1% of the total human skin surface. Even though the foreign agents,
especially  the  water-soluble  ones,  may be  able  to  penetrate  into  the  skin  via  these  skin
appendages at a rate which is faster than through the intact area of the stratum corneum. This
trans-appendage  route  of  percutaneous  absorption  has,  at  steady  state,  a  very  limited
contribution  to  the  overall  kinetic  profile  of  transdermal  permeation.  Therefore,  the
transdermal permeation of most neutral molecules can, thus, be considered as, a process of
passive diffusion through the intact stratum corneum in the interfollicular region.
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                             Figure 2: Routes of transdermal delivery of drug
TRANSDERMAL PATCHES31
A transdermal patch or skin patch is a medicated adhesive patch that is placed on the skin to
deliver a specific dose of medication through the skin and directly into the bloodstream.
Various drugs which are administered through skin patches include scopolamine (for motion
sickness),  nicotine  (for  quitting  smoking),  estrogen  (for  menopause  and  to  prevent
osteoporosis), nitroglycerin (for angina), lidocaine (to relieve the pain of shingles) and many
more drugs.
MECHANISM OF ACTION OF TRANSDERMAL PATCHES27
 The application of the transdermal patch and the flow of the active drug constituent from the
patch to the circulatory system via skin occur through various methods. 
1. Iontophoresis  
2. Electroporation  
3. Ultrasound  
4. Microscopic projection 
Iontophoresis
  It passes a few milli amperes of current to a few cm2 of skin through the electrode placed in
contact with the formulation, which facilitates drug delivery across the barrier. This technique
is mainly used for pilocarpine delivery to induce sweating as part of cystic fibrosis diagnostic
test.
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Electroporation  
 Electroporation is a technique of application of short, high-voltage electrical pulses to the
skin. After electroporation, the permeability of the skin for diffusion of drugs is increased by
4 times.  The electrical pulses are believed to form transient aqueous pores in the stratum
corneum, through which drug transport occurs.
Ultrasound
Use  of  ultrasound,  particularly  low  frequency  ultrasound,  has  been  shown  to  enhance
transdermal  transport  of  various  drugs  including  macromolecules.  It  is  also  known  as
sonophoresis. 
Microscopic projection
In this method, microneedles are used to facilitate transdermal drug transport through the
skin. Needles ranging from approximately 10-100 μm in length are arranged in arrays. When
pressed into the skin, the arrays make microscopic punctures that are large enough to deliver
macromolecules, but small enough that the patient does not feel the penetration or pain. The
drug is  surface  coated  on the  microneedles  to  aid  in  rapid  absorption.  They are  used  in
development of cutaneous vaccines for tetanus and influenza.
Selection of the drug for transdermal drug delivery system 
Before  the  development  of  the  transdermal  drug  delivery  system  of  any  drug,  various
pharmacokinetics  and  pharmacodynamic  properties  are  taken  into  consideration.  Typical
requirement for transdermal delivery of drug includes 
* Low molecular weight ranging from 500 to 1000 Daltons. 
*Low melting point (150-2000F).
 *Aqueous solutions neither too acidic nor basic (between 5 and 9 pH units) 
* Preferable lipid/water co-efficient i.e. partition coefficient.
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*The most important requirement of the drug to be delivered transdermally is demonstrated
by need for controlled delivery, such as short half-life and adverse effects associated with
other routes or complex oral route or IV dose regimen. 
* Drugs which get extensively metabolized in the hepatic first pass effect.
BASIC COMPONENTS OF TRANSDERMAL DRUG DELIVERY SYSTEMS28 
The components of transdermal devices include: 
1. Polymer matrix or matrices
 2. The drug
 3. Permeation enhancers
 4. Other excipients 
Polymer matrix 
The polymer controls the release of the drug from the device. The following are the criteria
should be satisfied for a polymer to be used in the transdermal system: 
*  The  polymer  should  be  stable,  non  reactive  with  the  drug,  easily  manufactured  and
fabricated into desired product and inexpensive.
*The polymer and its degradation products must be non toxic to the host. 
* The mechanical properties of the polymer should not deteriorate excessively when large
amounts of active agent are incorporated in to it.
e.g:  Cellulose derivatives, Polybutadiene, Neoprene, Polyamides etc.
Drug
The following are some of the desirable properties of a drug for tansdermal delivery: 
* The drug should have a molecular weight less than 1000 Daltons. 
* The drug should have affinity for both- lipophilic and hydrophilic phases. 
* The drug should have low melting point. 
* The drug should be potent with a daily dose of the order of a few mg/day. 
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* The half life of the drug should be short. 
* The drug must not induce a cutaneous irritation or allergic response. 
* Drug which degrade in the GI tract or inactivated by hepatic first-pass effect are suitable
candidates for transdermal delivery. 
* Drugs which have to be administered for a long period of time or which cause adverse
effects to non-target tissues can also be formulated for transdermal delivery. 
Permeation enhancers
These are the compounds which promote skin permeability by altering the skin & increase
the flux of a desired penetrant. 
The flux,J, of drugs across the skin can be written as: 
 J = D dc/dx                                                                 (2)
D = Diffusion coefficient 
C =Concentration of the diffusing species. 
Permeation enhancers are hypothesized to affect one or more of these factors to achieve skin
penetration enhancement.  A large number of compounds have been investigated for their
ability to enhance stratum corneum permeability. These may be conveniently classified under
the following main headings: 
a. Solvents 
The  compounds  increase  penetration  possibly  by  swelling  the  polar  pathway  and  by
fluidizing lipids. 
E.g  :  Methanol,  Ethanol,  Dimethyl  sulfoxide,  Dimethyl  acetamide,  Propylene  glycol,
Glycerol. 
b. Surfactants
These compounds are proposed to enhance polar pathway transport, especially of hydrophilic
drug. The stability of a surfactant to alter penetration is a function of the polar head group and
the  hydrocarbon  chain  length.  These  compounds  are  skin  irritants  therefore,  a  balance
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between penetration enhancement and irritation have to be considered. Anionic surfactants
can  penetrate  and  interact  strongly  with  the  skin.  Cationic  surfactants  have  also  shown
penetration properties but are not used because of their toxic nature.
Examples of commonly used surfactants are: 
Anionic  surfactants:  Dioctylsulphisuccinate,  Sodium  lauryl  sulphate,  Decodecyl
methylsulphoxide.
 Nonionic surfactants: Pluronic F127,Pluronic F68 etc. 
Bile salts: Sodium taurocholate, Sodium deoxycholate, Sodium taurolglycocholate.  
c. Binary system 
These systems apparently open up the heterogeneous multilaminate pathway as well as the
continuous pathways. 
e.g : Propylene glycol-oleic acid and 1,4-butane diol-linoleic acid.
d. Miscellaneous chemicals 
These  include  urea,  a  hydrating  and  keratolytic  agent,  N,N-dimethyl  –m-toluamide,
Calciumthioglycolate.
4. Other excipients 
*Adhesives 
* Backing membrane 
Adhesives 
Adhesive systems should fulfil the following criteria: 
* Should not irritate or sensitize the skin or cause an imbalance in the normal skin flora
during its contact time with the skin. 
* Should adhere to the skin aggressively during the dosing interval without its position being
disturbed by activities such as bathing, exercise etc. 
* Should be easily removed. 
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* Should not leave any unwashable residue on the skin. 
E.g. Polyacrylates, Polyisobutylene and Silicon based adhesive.
Backing membrane 
The primary function is to provide a good bond to the drug reservoir, prevent drug from
leaving  the  dosage  forms  through  the  top.  It  is  impermeable  substance  that  protects  the
product during use on the skin.
e.g:  Metallic  plastic  laminate,  Occlusive base plate  (aluminium foil),  Adhesive foam pad
(flexible polyurethane) etc.  
APPLICATIONS OF TRANSDERMAL PATCHES29,30  
1. Transdermal patch of nicotine, which releases nicotine in controlled doses to help with
cessation of tobacco smoking.
 2. Nitroglycerine patches are sometimes prescribed for the treatment of Angina. 
3. Clonidine, the antihypertensive drug and ketoprofen, the non-steroidal anti inflammatory
drug are also available in the form of transdermal patches.
 4. Transdermal form of the MAOI selegiline, became the first transdermal delivery agent for
an antidepressant. 
5. Two opioid medications used to provide round-the-clock relief for severe pain are often
prescribed in patch form- Fentanyl (marketed as Duragesic) and Buprenorphine (marketed as
BuTrans).
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                                        REVIEW OF LITERATURE
Meenakshi M et al.(2016).,
67
Prepared lamivudine loaded maltodextrin based proniosomes 
by slurry method using different nonionic surfactants (Span 40, Span 60, Tween 60) in 
various concentrations.  The concentration of cholesterol& maltodextrin were kept constant. 
The interaction between drug and added exicipients were studied by FT-IR. Further the
proniosomes were evaluated for particle size distribution, drug content, entrapment 
efficiency, in- vitro drug release and kinetic studies. The stability study of optimized 
proniosomes was determined under refrigerated condition (4
0
C ± 2
0
C) and room temperature 
(25
0
C ± 2
0
C). The effect of surfactant concentration on vesicle size, entrapment efficiency 
and in-vitro drug release were studied. The highest entrapment efficiency of 95.02%& 
cumulative percentage drug release of 93.53% was found for formulation containing 
maltodextrin,span40 &cholesterol in the ratio 1:3:1.
Sankar et al. (2009).,
57
Designed hydrocortisone loaded proniosomes as a novel drug 
delivery approach for increasing its permeation through the skin. Hydrocortisone 
proniosomal gel was prepared by coacervation-phase separation method using different 
combinations of non-ionic surfactants, cholesterol and lecithin. Proniosome formulations 
were characterized for vesicle size, entrapment efficiency, and drug content uniformity. Span 
20: Span 40, Span 20: Span 60 and Span 20: Span 80, combinations showed good entrapment 
compared with Span: Tween combinations.The results of the study indicated that topical 
application of hydrocortisone in the form of proniosomes leads to prolonged action.
Goyal et al. (2011).,
53
Prepared and evaluated the anti inflammatory activity of gugul- lipid 
loaded proniosomal gel. The formulated proniosomal based gels were characterized for 
particle size, entrapment efficiency, in -vitro drug release and in -vivo anti-inflammatory 
activity using carrageenan induced rat hind-paw method. The result of the study showed that 
proniosomal formulation of gugul-lipids holds an immense potential for development of 
topical herbal anti-inflammatory formulation comparable to topical NSAIDs.
Ankur et al. (2007)., 
36
Demonstrated a proniosomal carrier system for captopril for the 
treatment of hypertension that is capable of efficiently delivering entrapped drug over an 
extended period of time. The potential of proniosomes as a transdermal drug delivery system 
for captopril was investigated by encapsulating the drug in various formulations of 
proniosomal gel composed of various ratios of sorbitan fatty acid esters, cholesterol, lecithin 
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prepared by coacervation-phase separation method. The formulated systems were 
characterized for size, vesicle count, drug entrapment, drug release profiles and vesicular 
stability at different storage conditions. Stability studies for proniosomal gel were carried out 
for 4 weeks. The results of the study showed that proniosomes are a promising prolonged 
delivery system for captopril and have reasonably good stability characteristics.
Ibrahim et al. (2005).,
54
Investigated permeation of ketorolac across excised rabbit skin from 
various proniosomal gel formulations using franz diffusion cell. Proniosomes prepared with 
Span 60 provided a higher ketorolac flux across the skin than did those prepared with Tween 
20. A change in the cholesterol content did not affect the efficiency of the proniosomes and
the reduction in the lecithin content did not significantly decrease the flux (P>0.05). The 
encapsulation efficiency and size of niosomal vesicles formed by proniosome hydration were 
also characterized by specific HPLC and SEM. The results of the study indicated that 
proniosome may be a promising carrier for ketorolac and other drugs, especially due to their 
simple production.
Ammar et al. (2011).,
34 
Formulated different proniosomal gel bases. They were characterized 
by light microscopy, and assessed for their drug entrapment efficiency, stability, and their 
effect on in- vitro drug release and ex- vivo drug permeation. The lecithin-free proniosomes 
prepared from Tween 20: cholesterol (9:1) proved to be stable with high entrapment and 
release efficiencies. The in- vivo behaviour of this formula was studied on male rats and 
compared to that of the oral market product. The result of the study showed that the 
investigated tenoxicam loaded proniosomal formula proved to be non-irritant, with 
significantly higher anti inflammatory and analgesic effects compared to that of the oral 
market tenoxicam tablets.
You Fang et al. (2001).,
55 
Conducted the skin permeation of estradiol from various 
proniosomal gel formulations across excised rat skin in- vitro. Proniosomes with Span 40 and 
Span 60 increased the permeation of estradiol across skin. Presence or absence of cholesterol 
in the lipid bilayers of vesicles did not reveal difference in encapsulation and permeation of 
the estradiol. He concluded that the types and contents of non-ionic surfactant in proniosome 
are important factors affecting the efficiency of transdermal estradiol delivery. The results of 
the study showed that the types and contents of non-ionic surfactant in proniosomes are 
important factors affecting the efficiency of transdermal estradiol delivery.
                                                                                                                Review of Literature
Dept of Pharmaceutics, KMCH College of Pharmacy Page 20
Kapil et al. (2011).,
56 
Fabricated curcumin loaded proniosomes for topical delivery . The 
drug was encapsulated in the mixture of span80, cholesterol & di-ethyl ether by ether 
injection method. The prepared formulations were evaluated for size, angle of repose ,drug 
entrapment, hydration rate & stability under various storage conditions. The in-vitro drug 
release study was also performed using albino rat skin. Formulation having the Span80: 
cholesterol ratio of 1:4 showed prolonged release of 61.8% at 24
th
hr. All the prepared 
formulations showed entrapment efficiency of 82.3-86.8%.Stability data of the preparation 
stored under refrigerated condition, room temperature & elevated conditions did not show 
much variations.  Hence they concluded that proniosomes are very stable and promising 
prolonged delivery system for curcumin.     
Kakkar et al. (2010).,
58 
Prepared non-ionic surfactant vesicles of valsartan by coaservation 
phase separation method. The prepared systems were characterised for encapsulation 
efficiency, shape, size and in vitro drug release. Stability study was carried out to study the 
leaching out of the drug from the proniosomal preparation. The encapsulation efficiency of 
proniosomes prepared with Span 60 was superior to that prepared with Span40. The 
formulation with 9:2:9 ratio of Span 60, cholesterol and lecithin gave maximum 
encapsulation efficiency of 71.50% and release rate of 75% over a period of 24 hrs as 
compared to other formulations.  
H Priyanka et al. (2015).,
59
Worked on formulation and evaluation of low orally 
bioavailable drug carvedilol loaded proniosomes as a transdermal drug delivery system. The 
proniosomal gel was prepared by coacervation phase separation method by using different 
surfactants like spans 20, 60, 80, tween 20, 80, soya lecithin and cholesterol.The prepared
formulations were evaluated for vesicle size analysis, surface morphology studies, 
encapsulation efficiency, and in-vitro drug release. The formulations prepared from span 
showed smaller vesicle size & high encapsulation efficiency compared to the vesicles
prepared from tween. They found out that the vesicles prepared out of span 60 showed 
highest encapsulation efficiency of 95% & drug release of of 98% over a period of 12 hrs.
Ashish kute et al. (2012).,
60  
Developed perindopril erbumil loaded proniosomal gel by 
coaservation phase separation method. Different surfactant ratios were employed for the 
preparation. Vesicle size, surface morphology, encapsulation efficiency, in -vitro, stability 
study data were evaluated. The size of the vesicles ranged between 15.13µm, encapsulation 
efficiency between 70.72-76.43%. In- vitro release studies showed that as the lipophilicity 
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increases, the drug release decreases. They showed that the, proniosomal gel with T20:T60 
in ratio of 9:1 showed the highest % of drug release (80.03%) over period of 24 hrs.
Ajay et al. (2008).,
61
  Prepared, characterized and optimized the aceclofenac proniosomes 
using central composite design and carried out stability studies. Preparation was done using 
slurry method. Three independent variables selected were molar ratio of drug to lipid (X1), 
surfactant loading (X2) and volume of hydration (X3). Based on central composite design, 16 
formulations were prepared. The prepared formulations were evaluated for percentage drug 
entrapment & mean volume diameter. Proniosomes with optimum responses were selected 
using the polynomial equations & contour plots developed using central composite design.
Both the proniosomal preparations stored under refrigerated condition & at room temperature 
were found to be stable.
Tamizharasi S et al. (2009).,
62 
Reported indomethacin loaded maltodextrin proniosome 
prepared by slurry method incorporating different ratios of surfactant to cholesterol ratio. The 
prepared proniosomes were optimized for % drug entrapment. Microscopic studies showed 
that all the particles have uniform size. The in -vitro release studies exhibited prolonged 
release for a period of 24hrs. The zeta potential values indicated that the proniosomes are 
stabilized by electrostatic repulsion forces. From stability studies they observed that the 
formation of niosomes were less at 4ºC, followed by 25ºC &37ºC. They concluded that 
proniosomes showed maximum entrapment & in -vivo evaluation with enhanced 
bioavailabilty & long lasting drug release profile.
Gamal M et al. (2010).,
39
Developed meloxicam loaded proniosomes as a carrier for 
transdermal delivery. They characterized the proniosomes for entrapment efficiency, surface 
morphology & in vitro drug release. Proniosomes prepared using spans & tweens exhibited 
high encapsulation efficiency. The prepared proniosomes considerably improved drug 
penetration & reduced lag time. The formulation prepared from span60 showed greater 
penetration through skin than those prepared using tween80. The results showed that the 
proniosomal gel showed better activity than meloxicam gel which showed that these are 
capable carrier as a transdermal delivery.
Raja K et al. (2011).,
63 
Fabricated glipizide loaded maltodextrin based proniosome by slurry 
method with different ratios of surfactant & cholesterol. The formulations were subjected to 
compatibility studies , angle of repose, SEM, entrapment efficiency, in vitro release study & 
stability study. The formulation having surfactant :cholesterol ratio 3:2, was found to be the 
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best formulation with highest entrapment efficiency of 84.25% , maximum drug release rate 
of  99.23% at the end of 24
th
hr and follows zero order kinetics.  The formulation showed 
appropriate stability when stored under refrigerated condition compared to the reconstituted 
niosomes.
Anahita Fathi et al. (2009).,
64
  Established the effect of hydrophilicity & hydrophobicity of 
surfactants on drug solubility, surface morphology, stability & skin permeation of haloperidol 
from different formulations. Formulations prepared with single surfactant showed more 
permeation of the drug than the formulations prepared with 2 surfactants. The number of 
carbons in the alkyl chain of the non-ionic surfactant affected the in vitro permeation of HP 
through the epidermis and the skin permeation was increased with increase in hydrophilic–
lipophilic balance (HLB) value of the surfactant. They concluded that the interfacial tension 
and surfactant hydrophobicity are useful for elucidating mechanism of skin permeation and 
for comparing drug ﬂuxes from different proniosomal formulations.
Mohamed et al. (2010).,
65
Developed a low dose proniosomal gel containing celecoxib for 
the treatment of osteoarthritis. All the prepared formulations were subjected to 
physicochemical evaluations and anti inflammatory studies. The entrapment was greater than 
90%. The vesicle shape was determined with the help of transmission electron microscopy. 
The vesicle size, size distribution, and polydispersity studies were performed using photon 
correlation spectroscopy. Anti-inflammatory studies were performed using the rat hind-paw 
oedema induced by carrageenan (1% w/v). The obtained results showed that the proniosomal 
formulation significantly improved the extent of celecoxib absorption than conventional 
capsule. 
Mokhtar et al. (2008).,
66 
Fabricated  proniosomal gels or solutions of flurbiprofen based on 
span 20 (Sp 20), span 40 (Sp 40), span 60 (Sp 60), and span 80 (Sp 80) without and with 
cholesterol. The influence of different processing and formulation variables was 
demonstrated. The release of the prepared niosomes in phosphate buffer (pH 7.4) was 
illustrated. Results indicated that the EE% followed the trend Sp 60 (C18) > Sp 40 (C16) > 
Sp 20 (C12) > Sp 80 (C18).
Pankaj S et al .(2013).,
42
Formulated proniosomal gel of clotrimazole using lecithin & 
cholesterol as encapsulating agents & span and tween of different grades. The gel was 
evaluated for pH, vesicle size, % encapsulation, drug diffusion study, ex-vivo skin permeation 
and ex-vivo drug deposition study &stability study. It was found that formulation containing 
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span60 showed prolonged release compared to conventional formulation and showed 2 fold 
increase in drug deposition in the skin compared to conventional cream. Results from 
antifungal study showed that the developed proniosomal gel is more efficient than the 
marketed formulation. Stability studies also revealed that the proniosomal gels were stable at 
5±3ºC & 25±2ºC. They concluded that the proniosomal gel of clotrimazole could be 
formulated for sustained release.
Vivane F et al. (2012).,
68
Investigated proniosomal carrier systems for acyclovir. Acyclovir 
proniosomal carrier systems were prepared by three different methods i.e slow spray coating 
method, coaservation phase separation method & slurry method using different carriers & 
were subjected to in-vitro & ex-vivo studies. Characterization of the prepared proniosomes 
were done by particle size analysis, microscopical examination, IR spectroscopy, DSC, in-
vitro dissolution and storage studies. Results showed that the prepared vesicles were 
spherical, discrete with no aggregation. It was observed that in in -vitro release studies 
initially the drug release was faster from proniosomes followed by relatively slower release 
up to 8 hours. Ex vivo intestinal permeability studies showed a faster drug flux from the 
proniosome formulations than from drug solution and also the formulations were stable at 
different temperatures. They concluded that the proniosomes are promising carrier for 
acyclovir.
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                                         AIM AND OBJECTIVES
AIM:
The absorption of drugs through the transdermal route improves bioavailability of drugs that 
might otherwise be metabolized by first-pass during their passage through the gastrointestinal 
tract. Drug absorption from the transdermal route is mainly via passive diffusion through the 
lipoidal membrane. Thus,  transdermal  route  of drug  delivery  has  attracted  the  attention  
worldwide  for optimizing the drug delivery.
   Metronidazole is an antifungal agent & can be given through topical route. It has been used 
in the treatment of various topical as well as systemic diseases which includes: acne, pelvic 
inflammatory disease, endocarditis, bacterial vaginosis, amoebiasis, trichomoniasis . It has 
low aqueous solubility, which can affect its dissolution leading to poor BA.  Incorporation 
into proniosomes can lead to reduced dose, improved bioavailability and prolonged release,
hence the drug of choice.
      The aim of study is to formulate and develop Metronidazole Benzoate loaded 
proniosomes with different ratios of cholesterol and non-ionic surfactants and incorporation 
of proniosomes into transdermal patch to achieve prolonged release of drug on topical 
administration.
OBJECTIVES:
 To prepare proniosomes and evaluate them for angle of repose, drug content, particle 
size, hydration rate, encapsulation efficiency, in-vitro release studies& ex-vivo drug 
permeation studies.
 To incorporate proniosomes into transdermal patch. 
 To evaluate proniosomal transdermal patch.
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                                          PLAN OF WORK
 Collection of raw materials
 Review of literature
 Calibration curve for Metronidazole benzoate
 Preparation of proniosomes
 Evaluation of proniosome 
            1. Angle of repose   
            2. Optical microscopy
            3. Drug content analysis
           4. Entrapment efficiency
           5. In – vitro drug diffusion study
       6. Ex-vivo permeation study
           7. Rate of spontaneity
            8. Vesicle size analysis
          9. Anti- fungal study
          10. Scanning electron microscopy
 Incorporation of proniosomes into transdermal patch.
 Evaluation of proniosomal transdermal patch.
              1. Physical appearance 
              2. Thickness
              3. Folding endurance
              4. % Moisture loss
              5. % Moisture absorption
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                6. Drug content determination
                7. Water vapor transmission rate
                8. % Flatness
                9. In-vitro diffusion study
               10. Drug release kinetic data analysis
               11. Stability study
                                                                                                                   Drug Profile      
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                                               DRUG PROFILE
                                           METRONIDAZOLE BENZOATE22,23,24
Synonym                   : Benzoyl metronidazole
Molecular formula   : C13H13N3O4
IUPAC name             :2-(2- methyl-5- nitro-1-H-imidazole-1-yl)ethyl benzoate
Molecular weight      : 275.3 g/mol
Description                : A white or cream coloured crystalline powder or flakes.
                                      200mg of Metronidazole benzoate is equivalent to 125mg of 
                                      Metronidazole.
Structure of Metronidazole Benzoate:
Category                          : Antiamoebic, antiprotozoal , antibacterial
Solubility                         : Practically insoluble in water, freely soluble in methylene 
                                            chloride, soluble in ethanol.
Route of administration : Oral, rectal, vaginal, topical.
Dose                                  :  Amoebiasis- Equivalent of 400mg of metronidazole thrice daily
                                             for 5-10 days.  Anaerobic infections: 500mg every 6 hrs.
Half-life                            : 7-8hrs
Melting point                   : 98-102ºC
Uses                                   : Pelvic inflammatory disease, endocarditis, bacterial vaginosis,
                                            amoebiasis, trichomoniasis.   
Mechanism of action        : It is a bactericidal, amoebicidal & trichomonicidal drug. It is 
                                              reduced by low redox potential electron transfer proteins           
                                              (nitroreductases- ferredoxin) to unidentified polar products
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                                            which lack the nitrogroup.  These reduction products inhibit 
                                             nucleic acid synthesis by  disrupting the DNA of
                                             microbial cells.
Pharmacokinetic profile : Oral B.A = 60%
                                              PPB        = 20%
                                               Vd          = 0.510- 1.10L/Kg
ADR                                  : More serious – Breathing difficulty, swelling of lips,tongue,face  
                                                                      or throat
                                              Less serious – Mild burning or stinging when applied,
                                                                      numbness or tingly feeling in hand & feet
                                                                      cough , stuffy nose, sore throat & cold
                                                                      vaginal itching
Storage                              :  Store below 25ºC, protected from light.
Excipient Profile
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EXCIPIENT PROFILE
CHOLESTEROL
13
Synonym :Cholesterin, Cholesterolum 
Chemical formula    : C27H46O
Molecular weight     : 386.6535g/mol
Chemical name : Cholest-5-en-3ß-ol
Description : Cholesterol occurs as white or faintly yellow, odourless, pearly 
leaflets, needles, powder or granules. On prolonged exposure to light
& air, it acquires a yellow to tan colour. 
Structure of cholesterol:
Functional category : Emollient, emulsifying agent
Melting point     : 148.5ºC
Boiling point             : 360ºC
Water solubility       : 00.095mg/L (at 30ºC)
Applications             : It is used in cosmetics & topical pharmaceutical formulations as an 
emulsifying agent. It imparts water absorbing power to ointments. It is 
the major sterol of higher animals, & is found in all body tissues, 
especially in brain &spinal cord.
Excipient Profile
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SPAN 40
13
Synonym                       : Sorbitan monopalmitate
Chemical formula        : C22H42O6
Molecular weight         : 402.57g /mol
Structure of span 40    :
Properties of span 40
Related categories          : Biochemical reagents, cleaner, detergent
Description                  : Non-ionic
Melting point                  : 46-47ºC
HLB value                       : 6.7±10
Excipient Profile
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SPAN 60
14
Synonym : Sorbitane monostearate, sorbitan stearate
Chemical name : Span60
Chemical formula : C24H46O6
Description : It is an ester of sorbitan & stearic acid & is sometimes referred to as
synthetic wax. It is an non-ionic surfactant with emulsifying, wetting & 
dispersing properties.
Structure of span 60:
Related categories : Biochemical reagent, cleaner, detergent
HLB value             : 4.7
Applications          : Span 60 has been used in a study to assess encapsulation of doxorubicin 
in niosomes as a route to tumour targeting. It has been also been
employed to investigate the use of non-ionic surfactants as contrast 
agents for the use in diagnostic ultrasound.
Excipient Profile
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TWEEN60
15
Synonym : Polysorbate monostearate 
Chemical name : Tween60
Chemical formula : C64H42O26
Description : It is a yellow oily liquid with characteristic odour, soluble in ethanol, 
insoluble in mineral oil & vegetable oil.
Structure of tween 60:
Molecular weight : 1312g/mol
Saponification value : 45-55
Acid value : ≤2
Specific gravity : ≈1.10
Viscosity : ≈400mPas
Flash point : 149ºC
HLB value : 14.9
Moisture content : 3%
Surface tension :  42.5cps
Applications : Emulsifying agent, non-ionic surfactant, solubilising agent, wetting 
agent, suspending agent.
Excipient Profile
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TWEEN20
69
Synonym               : Polysorbate20, PEG (20) sorbitan monolaurate, Alkest TW20
Chemical name : Polyoxyethylene (20) sorbitan monolaurate
Chemical formula : C58H114O26
Description            : Clear yellow to yellowish green viscous liquid
Structure of tween 20:
Molecular weight: 1227.54g/mol
Density                 : 1.1g/mL
Boiling point       : >100ºC
HLB value           : 16.7
Applications        :  * It has been widely used as an excipient in pharmaceutical applications 
to stabilise emulsions &suspensions.
*As a wetting agent in flavoured syrups.
*As a washing agent in immunoassays.
* As a solubilising agent of membrane proteins.
*To stabilise purified protein derivative solution used in skin testing    
for tuberculosis exposure.
Excipient Profile
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HYDROXY PROPYL METHYL CELLULOSE
70
Synonym                  : Benecel MHPC, Hypromellosum, Methocel, Pharmacoat
Chemical formula  : Cellulose hydroxypropylmethyl ether
Description             : It is an odourless, tasteless, white or creamy white fibrous or granular 
powder
Structure of HPMC :
Where R is H,CH3 or CH3CH(OH)CH2
pH                           : 5.5-8.0 for 1% aqueous solution
Melting point          : 190-208ºC
Solubility                : Soluble in cold water, forming a viscous colloidal solution, practically
insoluble in chloroform, ethanol (95%), & ether, but soluble in mixtures 
of ethanol & dichloromethane, methanol& dichloromethane & mixtures
of water & alcohol.
Applications         : It is widely used in oral, ophthalmic, & topical formulations. In oral 
products, it is primarily used as tablet binder, in film coating, as matrix 
for extended release tablet formulations.
Excipient Profile
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LECITHIN
18
Synonym : Lecithol,Vitellin, Kelecin, Granulestin
Chemical name : 1,2- diacyl-sn-glycero-3-phosphocholine
Description : Vary in colour from brown to light yellow
Structure of lecithin:
Functional category : Emollient, emulsifying agent, solubilising agent
Solubility                   : Soluble in aliphatic & aromatic hydrocarbons, halogenated 
hydrocarbons & mineral oil.
Density : 0.5g/cm
3
Isoelectric point : 3.5
Compatibility : Incompatible with esterase owing to hydrolysis.
Stability : Lecithin decomposes at extreme pH
Moisture content : Hygroscopic in nature
Specific gravity : 0.97g/cm
3
Safety : Non-toxic, excessive consumption may be harmful.
Applications              : Lecithin is used in wide variety of pharmaceutical preparations like
aerosol inhalations, i.m injections & oral suspensions. It is mainly 
used as dispersing, emulsifying & stabilising agent.
Excipient Profile
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LACTOSE
16
Synonym               : Fast flow, Lactochem, Tablettose, Zeparox, Granulac, Microfine, 
Pharmatose.
Molecular weight : 342.30g/mol
Description            : It is white to off white crystalline powder. It is odourless & slightly 
sweet in taste.
Structure of lactose:
Functional category : Tablet & capsule diluent
Solubility :  It is practically insoluble in chloroform, ethanol, ether & partially 
soluble in water.
Loss on drying : Less than 1.0% for monohydrate & 0.5% for anhydrate forms.
Storage & Stability : Under humid conditions above 80% mould may grow. It develops 
brown colour on storage. It should be stored in well closed 
container in a cool &dry place.
Applications : Lactose is widely used as filler or diluents in tablets & capsules. It is 
also used as a carrier for inhalational & lyophilized products.
Excipient Profile
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MANNITOL
17
Synonym : Manita, Manitol, Manna sugar, Mannit, D Mannite, Mannite,  
Mannitolum
Chemical name : D mannitol
Molecular weight: 182.17g/mol
Description : It occurs as a white, odourless, crystalline powder or free flowing 
granules. It has a sweet taste & imparts a cooling sensation in the mouth. 
It shows polymorphism.
Chemical formula : C6H14O6
Structure of mannitol:
Functional category: Lyophilisation & plasticizing agent, sweetening agent, tablet &
capsule diluents, tonicity agent.
Stability & Storage : Mannitol is stable in dry state & in aqueous solution. It should be 
stored in cool, dry place.
Applications : In pharmaceutical preparations it is used as a diluent. It has been used
to prevent thickening in aqueous antacid suspensions, as a plasticizer 
in soft gelatine capsules, as a carrier in dry powder inhalers & also in 
lyophilised preparations to improve its appearance.
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                                 MATERIALS AND METHODS 
Table 1: List of materials used 
                          Materials                 Supplier/ Manufacturer 
Span40 Lobachemie pvt. Ltd, Mumbai 
Metronidazole benzoate Sanofi Aventis, Goa 
Span60 Lobachemie pvt. Ltd, Mumbai 
Tween60 Lobachemie pvt. Ltd, Mumbai 
Tween20 Lobachemie pvt. Ltd, Mumbai 
Lactose SD Fine Chemicals, Mumbai 
Mannitol SD Fine Chemicals, Mumbai 
Cholesterol Lobachemie pvt . Ltd, Mumbai 
Lecithin Hi-Media laboratories pvt. Ltd, Mumbai 
HPMC Lobachemie pvt . Ltd, Mumbai 
Chloroform  Hi-Media laboratories pvt. Ltd, Mumbai 
Ethanol Finar Chemicals Ltd, Mumbai 
   
Table 2: List of instruments used 
                        Instruments                  Supplier/ Manufacturer 
Single pan analytical balance Amandi, Mumbai 
Hot air oven Technico, Mumbai 
Magnetic stirrer Remi, Mumbai 
Sonicator Sonics, USA 
Dessicator Sorbead, Mumbai 
Humidity chamber Technico, Mumbai 
Franz diffusion cell Self fabricated, Coimbatore 
UV spectrophotometer  Schimadzu, Schimadzu corporation, 
Philippines 
FT/IR  spectrometer 4100  Jasco, Johannesburg, South Africa 
Rotary vacuum evaporator Superfit, India 
Stability chamber Technico, Chennai, India 
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METHODOLOGY 
Determination of λmax of Metronidazole Benzoate: 
The drug solution of 10µg/ml was prepared in ethanol. The solution was sonicated for 10 
mins. This drug solution was scanned in the UV region of 200-400nm & the overlaid spectra 
was recorded. From the spectra, the λmax was found to be 309nm. 
Determination of Standard curve 
Weighed accurately 50mg of  Metronidazole Benzoate and dissolved in 2.5ml of ethanol . 
This was made up to 50ml with distilled water in a standard flask & sonicated for 3mins. 
Then the solution was serially diluted to get concentrations of 10, 20,30,40,50 µg/ml. The 
absorbance of the solutions were measured in UV spectrophotometer at 309nm. The 
calibration curve was plotted by taking concentration of the solution in µg/ml on X-axis & 
absorbance on Y-axis & regression co-efficient R2 was calculated. 
Drug excipient compatibility studies 
IR spectra matching approach was done for detecting any possible chemical interactions 
between the drug& the excipient. A physical mixture of the drug & the excipient (1:1) was 
prepared & mixed with suitable quantity of KBr. About 100mg of mixture was compressed to 
form a transparent pellet using a hydraulic press at6 tons pressure. It was scanned from 4000-
400cm-1 in FTIR spectrometer. The IR spectrum of the physical mixture was compared with 
the IR spectrum of the pure drug & matching was done to detect any appearance or 
disappearance of peaks. 
Surface morphology of proniosome using SEM32 
To detect the surface morphology of the proniosome , SEM of the complex was performed 
using Scanning Electron Microscope at STIC, Cochin University, Ernakulam .  Double sided 
carbon tape was affixed on aluminum stubs. The powder sample of proniosomes was 
sprinkled onto the tape. The aluminum stubs were placed in the vacuum chamber of a 
scanning electron microscope. The sample was observed for morphological characterization 
using secondary electron detector attached to scanning electron microscopy. 
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FORMULATION OF PRONIOSOMES 
The proniosomes were prepared using slurry method. The carrier was taken in RBF and the 
entire volume of surfactant dissolved in the organic solvent was added to form a slurry. The 
flask was then attached to the rotary evaporator & vacuum was applied until a dry free 
flowing powder was obtained. The flask was removed from the evaporator and kept under 
vacuum overnight. The obtained proniosomal powder was stored in sealed container at4ºC.  
Table3: Formulation table of proniosomes 
Formulation 
code 
F1 F2 F3 F4 F5 F6 F7 F8 F9 F10 F11 F12 F13 F14 
Drug(mg) 100 100 100 100 100 100 100 100 100 100 100 100 100 100 
Cholesterol(mg) 1000 1000 1000 
lecithin 
1000 1000 1000 1000 1000 1000 250 500 1000 1000 1000 
Span40(mg) 1000 2000             
Span60(mg)   1000 2000     250 1000 1000 1000 500 750 
Tween20(mg)     1000 2000         
Tween60(mg)       1000 2000       
Lactose(mg)         1000      
Mannitol(mg) 1000 1000 1000 1000 1000 1000 1000 1000  1000 1000 1000 1000 1000 
Chloroform(ml) 10 10 10 10 10      10 10 10 10 10 10 10 10 10 
Ethanol(ml) 5 5 5 5 5 5 5 5 5 5 5 5 5 5 
 
EVALUATION OF PRONISOMES 
Angle of repose33 
The angle of repose of dry proniosomal power was measured by funnel method. The 
proniosome powder was poured into a funnel which was fixed at a position  so that the orifice 
of the funnel is 2cm above the level surface. The powder flows from the funnel to form a 
cone on the surface & the angle of repose was then calculated by measuring the height of the 
cone & the diameter of the base. The angle of repose was then calculated from the following 
formula: 
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                                                       tanθ=h/r                                     (3) 
Where, 
            θ= angle of repose 
            h= height of the cone 
            r = radius of the cone base 
Table 4: Standard values for angle of repose 
                Angle of repose (º)                         Type of flow 
                     <25                           Excellent 
                    25-30                            Good 
                    30-40                         Satisfactory 
                     >40                              Poor 
 
Optical microscopy34 
It is done to confirm the vesicle formation. A thin layer of proniosomal powder was placed 
on cavity slide. A drop of water was added through the sides of the coverslip into the cavity 
silde while under microscope & observed.  
Drug content analysis35 
Proniosomes equivalent to 30mg of drug was taken in a standard volumetric flask. They were 
lysed with 10ml ethanol by shaking for 15min. Diluted to 100ml with distilled water & 
sonicated for 3min. Aliquots were withdrawn , absorbance was measured 
spectrophotometrically at 309nm & the drug content was calculated from the calibration 
curve. 
Entrapment efficiency36 
100mg of proniosome was dispersed in little warm water to allow the formation of niosomes. 
Then added 5% ethanol upto 10ml & sonicated for 10 min.  Then the dispersion was 
centrifuged at1800 rpm for 40 min at 5ºC . The clear fraction was diluted appropriately with 
distilled water  & measured the absorbance at 309nm. The % encapsulation was calculated 
from the equation. 
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  % Encapsulation efficiency = ( Total drug- Free drug / Total drug) ×100            (4) 
In-vitro drug diffusion study through egg membrane 
Preparation of egg membrane37: 
From local departmental store egg was purchased. The skin was removed carefully from the 
outer region of the egg and separated from the underlying membrane. The outer skin of egg 
was removed with the help of 0.1 N HCl with constant stirring. After separating the full 
membrane, the membrane was washed with using phosphate buffer pH 7.4. The membrane 
was now used for further experimental work. 
Drug diffusion through egg membrane38: 
The in-vitro diffusion study was done using Franz Diffusion Cell. The capacity of the 
receptor compartment is 15ml. The egg membrane was mounted between the donor & the 
receptor compartments. Weighed amount of proniosomal powder (100mg)  was placed in the 
donor compartment  &the receptor compartment was filled with 5%ethanol . The receptor 
fluid was stirred continuously by a magnetic stirrer. At each sampling interval , samples were 
withdrawn for a period of 8hrs & were replaced by equal volumes of fresh receptor fluid to 
maintain sink condition. Withdrawn samples were analysed  spectrophotometrically  at 
309nm. 
Ex-vivo skin permeation study39,40(optimised batch) 
The permeation of Metronidazole Benzoate from proniosomal powder was investigated by 
using in-vitro Franz Diffusion Cell. The abdominal chicken skin was obtained from slaughter 
house & adhering subcutaneous fat was carefully cleaned. To remove the extraneous debris 
&leachable enzymes, the dermal side of the skin was kept in contact with physiological saline 
solution for 1hr before starting the permeation experiment. 
The skin was mounted on the receptor compartment with the stratum corneum facing towards 
the donor compartment. The receptor compartment was filled with 15ml of 5% ethanol 
maintained at 37ºC & was constantly stirred using a magnetic stirrer. 1g of proniosomal 
powder was placed on the skin in the donor compartment. . At each sampling interval , 
samples were withdrawn for a period of 12hrs & were replaced by equal volumes of fresh 
receptor fluid to maintain sink condition. Withdrawn samples were analysed  
spectrophotometrically  at 309nm. 
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Figure 3: Abdominal skin of chicken 
Rate of spontaneity( hydration)41 
10 mg of proniosomal powder (optimized batch) was transferred to a test tube & spread 
uniformily . 1 ml of 0.9% saline solution was added along the sides of the walls & kept aside 
without agitation . After 15 min  a drop was withdrawn &placed on Neubars chamber  & the  
no:of  niosomes eluted from proniosomes were counted. 
Vesicle size analysis35 (optimized batch) 
Hydrated proniosomal powder was observed under optical microscope at 100X 
magnification. The sizes of 100-200 vesicles were measured using calibrated stage & eye –
piece micrometer fitted in optical microscopy. 
Anti-fungal study42 
Anti –fungal study was carried out to ascertain the biological activity of the optimized 
formulation& compared with the standard drug(pure Metronidazole) against Candida 
albicans. 
A layer of Sabouraud dextrose agar media(20ml) was seeded with 0.2ml of the test micro-
organism & allowed to solidify in the petri-plate. Cups were made with sterile borer at4mm 
diameter on the solidified agar layer.  50 mg of the optimized formulation was taken 
&suspended in normal saline. The 12thhr release sample solution was poured into the cup for 
microbial assay. After keeping the petri-plates at room temperature for 4hr, the plates were 
incubated at 37ºC for 24 hrs. The diameter of zone of inhibition was measured. 
FORMULATION OF TRANSDERMAL PATCHES43 
The optimized batch of proniosome was loaded to the transdermal patch prepared by mixing 
200mg HPMC &  2% propylene glycol in solvent  chloroform:ethanol(2:1)  & poured into a 
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petri plate . The rate of evaporation of solvent was controlled by placing an inverted funnel 
over the petri plate . After 24 hrs the dried film was take out .  
EVALUATION PARAMETERS OF PATCH 
Physical appearance 
 All the transdermal films were visually inspected for colour, clarity, flexibility and 
smoothness. 
Thickness uniformity44 
The thickness of the formulated film was measured at 5 different points using a Vernier 
calliper and average thickness was calculated. 
Folding endurance45  
The folding endurance was measured manually for the prepared films. A strip of film 1cm2 
was cut and repeatedly folded at the same place till it broke. The number of times the film 
could be folded at the same place without breaking or cracking gives the value of folding 
endurance. 
Percentage moisture absorption46   
The films were weighed accurately and placed in a desiccator containing 100 ml of saturated 
solution of potassium chloride. After 3 days, the films were taken out and weighed again. The 
percentage moisture absorption was calculated using the formula:   
  % Moisture absorption= Final weight –Initial weight x100                      (5)                                                                                         
                                                          Initial weight 
Percentage moisture loss47 
The films were weighed accurately and placed in a desiccator containing anhydrous calcium 
chloride. After 3 days, the films were taken out and weighed again. The percentage moisture 
loss was calculated using the formula: 
  % Moisture loss= Initial weight – Final weight x100                                  (6) 
                                              Initial weight  
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Drug content determination48 
 A speciﬁed area of patch(1cm∗1cm) was dissolved in ethanol& made up the volume to 
100ml with distilled water. Then the whole solution was ultrasonicated for 15min. After 
ﬁltration, the drug was estimated spectrophotometrically at wavelength of 309nm and 
determined the drug content. 
Water vapour transmission rate37 
 Glass vial of equal diameter were used as transmission cells. The transmission cell was 
washed thoroughly and dried in an oven. The prepared film was fixed over the edge of the 
glass vial containing 3 gm of fused calcium chloride as a desiccant by using an adhesive. 
Then the vial was placed in a desiccator containing saturated solution of potassium chloride. 
The vial was taken out periodically and weighed for a period of 72 h. The water vapour 
transmission rate was calculated using the formula : 
                                                       WVT= WL/S                                          (7) 
Where, 
       W: Water vapor transmitting in g 
        L: Thickness of patch in cm 
        S:  Exposed surface area in cm  
Percentage flatness test49 
This test is done to ensure that the patches do not constrict with time. Three longitudinal 
strips were cut out from each film: 1 from the center, 1 from the left side and 1 from the right 
side. The length of each strip was measured and the variation in length because of non-
uniformity in flatness was measured by determining percent constriction, with 0% 
constriction equivalent to 100% flatness . The percentage constriction can be calculated using 
the formula: 
                                           % Constriction = I1-I2/ I1 x 100                     (8) 
     Where, 
                    I1: initial length of each strip 
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                    I2: Final length of each strip  
In-vitro diffusion study50 
The in-vitro diffusion study was done using Franz Diffusion Cell. The capacity of the 
receptor compartment is 15ml. The egg membrane was mounted between the donor & the 
receptor compartments. The formulated patch was cut into size of 2cm2 & was placed above 
the egg membrane in the donor compartment . The receptor compartment was filled with 
5%ethanol. The receptor fluid was stirred continuously by a magnetic stirrer. At each 
sampling interval, samples were withdrawn for a period of 12hrs & were replaced by equal 
volumes of fresh receptor fluid to maintain sink condition. Withdrawn samples were analysed  
spectrophotometrically  at 309nm. 
Drug release kinetics51 
To know the release kinetics , the data obtained from the in-vitro release profile was fitted 
into various models like 
* Zero order kinetic model:  cumulative percent drug release v/s time 
* First order kinetic model:  log cumulative percent drug remaining v/s time  
* Higuchi’s model:  cumulative percent drug release v/s square root of time    
*Korsmeyer- Peppas model : log cumulative percent drug release v/s  log time  
Zero order kinetics: 
It describes the system in which the drug release rate is independent of its concentration. 
                                                  Qt= Qo+Kot                                (9) 
Where,  
             Qt= Amount of drug dissolved in time t 
             Qo= Initial amount of drug in the solution , which is often 0 
             Ko=Zero order release constant 
If the release pattern obeys zero order, then the plot of Qt v/s t will give a straight line with a 
slope of Ko & an intercept at 0. 
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It is used to describe the drug dissolution of different types of modified release 
pharmaceutical dosage forms, as in case of some transdermal systems. The drug release from 
the dosage form is independent of the amount of drug remaining in the system. 
First order kinetics 
It describes the drug release from the systems in which the release rate is concentration 
dependent. 
                                              log Qt= log Qo+ kt/2.303               (10) 
Where, 
            Qt= Amount of drug released in time t 
            Qo= Initial amount of drug in the solution 
             k= First order release constant 
If the release pattern obeys first order, then the plot of log(Qo-Qt) v/s t will be straight line 
with a slope of kt/2.303 & an intercept at t= logQo. 
This type of dissolution profile is shown by pharmaceutical dosage forms containing water 
soluble drugs in porous matrices. The release of the drug is proportional to the drug 
remaining in its interior portion. 
Higuchi model 
According to this model, the fraction of drug from a matrix is proportional to the square root 
of time. 
                                             Mt/Mα=kHt1/2                                    (11) 
Where, 
           M
 t & Mα = Cumulative amounts of drug release at time t & at infinity 
           kH            = Higuchi dissolution constant( reflects formulation characteristics) 
If the Higuchi model of drug release (i.e Fickian diffusion) is obeyed, then the plot of Mt/Mα 
v/s t ½ will be straight line with slope kH. 
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Korsmeyer – Peppas model (Power law) 
The power law describes the drug release from the polymeric system in which the release 
deviates from Fickian diffusion. It is expressed using the following equation; 
                                          Mt/Mα= ktn                              (12) 
                                log[ Mt/Mα]= log k + n logt               (13) 
Where, 
             Mt & Mα= Cumulative amounts of drug released at time t & at infinity 
                   k       =Constant incorporating structural & geometrical characteristics of CR  
                                 device 
                  n         =Diffusional release exponent indicative of the mechanism of drug release  
                                 for drug dissolution 
To characterize the release mechanism , the dissolution data {Mt/Mα < 0.6} are evaluated. 
A plot of {Mt/Mα} v/s log t will be linear with slope n & intercept value of log k. Antilog of k 
gives the value of k. Peppas used the n value in order to characterize different release 
mechanisms as shown below: 
 Table 5: Release mechanisms 
                          ‘n’ value                           Drug release 
                             <0.5                              Fickian 
                          0.5<n<1                          Non - Fickian 
                               >1                       Case II transport 
 
Stability studies52 
The best formulation was tested for its stability. Stability studies were conducted according to 
the ICH guidelines, by storing the patch at accelerated temperature 40±2 °C and75± 5% RH 
for 45 days. The samples were withdrawn initially, 30th & 45th day and analyzed suitably for 
the physical characteristics, drug content and drug release.   
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                                 RESULTS AND DISCUSSION   
Determination of λmax of Metronidazole benzoate by UV spectrophotometer
The standard stock solution of Metronidazole benzoate was prepared in ethanol and scanned 
by UV spectrophotometer between 200-400nm. The UV absorption spectrum of 
Metronidazole benzoate showed λmax at 309nm & the same was used as analytical wavelength 
for further analysis.
Calibration curve of Metronidazole benzoate
The calibration curve for Metronidazole benzoate was developed in 5% ethanol at 
wavelength of 309nm using UV spectrophotometer. The linearity of the curve was found to 
be in the range of 10-50µg/ml. The regression coefficient value was found to be 0.9977.
                          Table 6: Calibration curve of Metronidazole benzoate
Concentration (µg/ml) Absorbance (nm)
10 0.0709
20 0.3145
30 0.612
40 0.8604
50 1.1862
                            
                            Figure4: Standard graph of Metronidazole benzoate
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Drug polymer compatibility studies
The IR spectra of drug and the drug with other excipients are shown. The FT-IR study 
showed that there is no major change in the position of peak obtained in drug alone and in the 
mixture of drug with excipients. Hence it can be confirmed that there are no major 
interactions between the drug & the excipients.
Figure5: FT-IR spectrum of Metronidazole benzoate pure drug
    Figure6: FT-IR spectrum of Metronidazole benzoate pure drug+ Cholesterol
Figure7: FT-IR spectrum of Metronidazole benzoate pure drug+ Lecithin
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Figure8: FT-IR spectrum of Metronidazole benzoate pure drug+ Span40
Figure 9: FT-IR spectrum of Metronidazole benzoate pure drug+ Span60
Figure10: FT-IR spectrum of Metronidazole benzoate pure drug+ HPMC
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Table7: Interpretation of FTIR spectra of drug and excipients
Drug & 
excipients
Functional group/ wave number(cm
-1
)
Mono -
substituted 
benzene
C=O 
stretching
N-O 
stretching
in 
aromatic 
ring
C=O 
stretching
Sp
2
CH 
stretching
C-N 
stretching
Metronidazole 
benzoate
710.64 1718.26 1523.97 1261.7 3421.58 1466.6
MB+ Cholesterol 710.158 1718.26 1532.97 1261.7 3415.8 1466.12
MB+ Lecithin 710.158 1718.26 1523.97 1261.7 3416.28 1466.6
MB+Span40 710.64 1718.26 1524.45 1266.65 3420.14 1467.08
MB+Span60 710.158 1718.26 1523.97 1266.16 3419.65 1467.08
MB+ HPMC 710.64 1718.26 1523.97 1261.22 3417.73 1466.6
EVALUATION OF PRONIOSOMES
Angle of repose
Table8: Results of angle of repose
Formulation code Angle of repose(º)
F1 21.9
F2 28.06
F3 35.2
F4 23.49
F5 21.14
F6 23.49
F7 23.9
F8 23.06
F9 25
F10 24.3
F11 24.15
F12 21.14
F13 22.6
F14 23.06
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From the above table, it was observed that all the formulations have good to excellent flow 
character. F12 formulation showed the best flow property.
Optical microscopy
Optical microscopy was performed by viewing the formulations under microcope. It was 
observed that all the preparations showed vesicle formation. The vesicles formed were found 
to be of uniform size & shape.
Drug content analysis
                                 Table 9: Results of drug content studies
Formulation code Drug content(%w/w)
F1 32.15
F2 23.11
F3 43.17
F4 34.67
F5 47.53
F6 51.15
F7 29.95
F8 56.66
F9 37.62
F10 39.19
F11 22.9
F12 75.36
F13 19.83
F14 29.76
From the drug content results, it was observed that formulations showed drug content in the 
range of 19.8-75.4%w/w. It was also observed that as the concentration of the sorbitan 
surfactants were increased, showed a decrease in the drug content. Conversely an increase in 
the concentration of the tween, gave increased drug content. The cholesterol content also 
influenced the amount of the drug present. Increasing the cholesterol content gave a rise in 
the drug concentration. This may be due to the lipophilic nature of the drug. In F3 cholesterol 
was replaced by lecithin, but it showed less drug content. The formulation F12 showed 
maximum drug content.
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Entrapment efficiency
Formulation code Percentage entrapment 
efficiency
F1 86.94
F2 77.09
F3 89.2
F4 72.8
F5 50.92
F6 45.85
F7 50.63
F8 65.87
F9 70.6
F10 83
F11 88.6
F12 89.85
F13 85.2
F14 88.5
Table 10: Results of entrapment efficiency
The entrapment efficiency was calculated from the absorbance obtained from the supernatant 
solution. The formulations showed entrapment efficiency in the range of 45.85-89.85%. 
Formulations made from span showed more encapsulation of the drug than the one made 
from tween. In F10 & F11 , the entrapment efficiency of  F11 was more due to increased 
cholesterol content as low cholesterol content gives rise to smaller vesicles hence reducing 
the E.E. From all the preparations , the formulation containing span 60: cholesterol ratio 1:1 
(F12)showed highest entrapment of the drug.
In –vitro drug diffusion study
Table11: Results of drug release studies 
Time
(hrs)
F1 F2 F3 F4 F5 F6 F7 F8 F9 F10 F11 F12 F13 F14
0.5 17.73 18.39 12.04 14.10 9.66 13.49 17.82 7.68 13.20 12.11 17.67 7.20 22.02 19.40
1 28.87 24.56 16.61 19.40 13.11 18.41 25.00 10.40 19.85 18.21 24.26 15.45 29.00 27.49
2 30.70 24.90 16.96 20.71 15.21 22.96 26.55 14.60 22.67 21.69 24.97 28.71 31.48 29.33
3 32.81 37.44 19.90 21.76 17.02 25.41 28.15 19.30 27.65 27.92 30.06 36.74 35.36 30.98
4 37.28 42.08 21.06 27.35 19.27 28.10 32.16 21.90 36.73 34.33 33.02 47.24 38.11 33.65
5 42.02 43.32 22.67 32.28 24.63 31.82 36.24 23.42 40.22 37.59 41.55 54.29 41.27 38.85
6 45.47 44.99 26.73 35.00 29.80 34.15 42.18 28.05 47.95 41.54 47.19 64.36 48.19 42.39
7 50.29 48.92 28.07 39.83 35.13 39.57 46.86 30.40 53.07 46.71 52.88 74.22 57.96 45.54
8 54.60 55.71 32.44 46.80 36.64 44.38 55.41 36.77 58.36 53.26 57.6 82.05 61.43 49.60
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Figure11:In-vitro comparative diffusion profile of proniosomal formulations containing 
Metronidazole Benzoate(F1-F3)
Fig12:In-vitro comparative diffusion profile of proniosomal formulations containing 
Metronidazole Benzoate(F4-F6)
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Figure13:In-vitro comparative diffusion profile of proniosomal formulations containing 
Metronidazole Benzoate(F7-F9)
Figure14:In-vitro comparative diffusion profile of proniosomal formulations containing 
Metronidazole Benzoate(F10-F12)
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Figure15:In-vitro comparative diffusion profile of proniosomal formulations containing 
Metronidazole Benzoate (F13&F14)
The in-vitro diffusion studies of all formulations were carried out using Franz diffusion cell 
with egg membrane as the semi-permeable membrane. The data obtained is given in table 11 
& plots were drawn between % cumulative release & time as shown in the above figures. It 
was observed that the formulations showed percentage cumulative release in the range of 
32.44-82.05% over a period of 8 hrs. The formulations made from span60 showed more 
release than the ones made from span40, tween 20&60. An increase in the cholesterol content 
showed an increase in drug diffusion. This may be attributed to the increased lipophilic 
nature of the proniosomal complex. F12 containing cholesterol: span60 in the ratio 1:1 was 
taken as the best formulation since it showed highest and optimum drug release over a period 
of 8 hrs. Replacement of the membrane stabiliser cholesterol by lecithin gave least dug 
diffusion. Hence it cannot be used as an effective membrane stabiliser.
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Evaluation of optimised formulation
Optimised formulation F12 was further subjected to the following studies:
Ex-vivo skin permeation study
Table 12: Results of ex-vivo skin permeation study
Time in hours Cumulative % permeation
0.5 5.8
1 11.75
2 18.14
3 21.90
4 26.96
5 35.69
6 46.52
7 56.43
8 63.99
9 66.45
10 71.92
11 75.82
12 84.71
Figure16: Drug permeation profile of F12 formulation
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The drug permeation of the formulation F12 through the abdominal skin of chicken was 
carried using Franz diffusion cell & the results are reported in table 12. The permeation 
profile was plotted between %cumulative drug permeated v/s time. It was observed that the 
formulation showed an optimum release of 84.71% over a period of 12 hrs.
Rate of spontaneity
The maximum benefit from the proniosome formulations can be speculated when abundant 
numbers of vesicles are formed after hydration. The number of vesicles formed per mm
3
was 
found to be 4.
Vesicle size analysis
It was done using optical microscope at 100X magnification. The vesicular size was found to 
be 13.65±0.24µm which is in correlation with the results obtained from SEM.
Vesicular size by SEM
The surface morphology of the formulated proniosomal derived niosomal vesicles 
(formulationF12) were confirmed by scanning electron microscopy. The vesicles are spherical 
in shape and smooth in nature.
Figure17: Scanning electron microscopic image of Metronidazole benzoate loaded 
proniosomal derived niosomes(optimised formulation)
Antifungal study
The microbiological assay of Metronidazole benzoate pure drug & 12
th 
hour release sample 
solution of F12 proniosomal formulation was carried out .The diameter of the zone of 
inhibition was taken as a measure of the drug’s antifungal activity. The zone of inhibition of 
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the pure drug & sample were found to be 26mm & 23mm respectively. Hence the results 
revealed that the developed proniosomal formulation is as effective as the pure drug in 
antifungal activity.
Figure18: Zone of inhibition obtained for Metronidazole benzoate proniosome (F12) and pure 
drug using Candida albicans
Calculation of total drug loading 
The formulation of the patch was made in such a way that each small circular patch of 
1.25cm radius (which is the radius of the Franz diffusion cell) contains 10mg of the drug. The 
total amount of drug to be loaded in the patch was calculated by measuring the total area of 
the petri dish in which the patch will be casted. The calculation was done as follows:
* Area of the small circular patch = 4.91cm
2
  
* Desired drug content in the small patch =10mg
* Area of the petri dish = 67.89 cm
2 
* Total amount of priniosomal powder to be loaded = 67.89 x 10 / 4.91 = 138mg   
Hence 138mg of the optimised proniosomal formulation (F12) was added in order to get 10mg 
per small circular patch.  
PREPARATION OF TRANSDERMAL PATCH
As per the methodology transdermal patches were prepared using HPMC by solvent casting 
method. Firstly the polymer was dissolved in particular solvent then the proniosome
formulation F12 was added into the solution. Plasticizer was added to the solution. This was 
casted on petridish. It was covered by funnel to control evaporation of solvent.   
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EVALUATION OF TRANSDERMAL PATCH
Physical appearance
All the transdermal films were visually inspected for colour, clarity, flexibility and 
smoothness.
Thickness 
5 patches were prepared and the thickness was measured using Vernier calliper. All the 
prepared patches showed similar thickness. The average thickness was found to be 0.226mm.
Folding endurance
The folding endurance of transdermal patches were measured manually. This test is important 
to check the ability of sample to withstand folding. Evaluation of folding endurance involves 
determining the folding capacity of the film subjected to frequent conditions of folding. This 
also gives an indication of brittle nature, less folding endurance indicates more brittleness.
The average folding endurance was found to be 43.
Percentage moisture loss
The average percentage moisture loss of the prepared patches was found to be 0.734%. The 
percentage moisture loss may be less due to the hydrophilic nature of the polymer.
Percentage moisture absorption
The average percentage moisture absorption of the prepared patches was found to be 4.69%. 
The percentage moisture absorption may be more due to the hydrophilic nature of the 
polymer.
Drug content determination
Drug content in a small circular patch was analyzed spectrophotometrically. Drug content of 
the patch was carried out to ascertain that the drug is uniformly distributed into the 
formulation. The prepared patch showed optimum drug content of 89.24%. Hence it can be 
concluded that the drug is uniformly distributed in the formulation.
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Water vapour transmission rate
Water vapour transmission determines the permeability characteristics of the patch. The 
water vapour transmission rate of the prepared patch was found to be 1.55g.Hence the result 
reveals that the formulation is permeable to water vapour.
Percentage flatness test
Table13: Results of % flatness test
The flatness study showed that the patch had the same strip length before & after their cuts, 
indicating 100% flatness. Thus no amount of constriction was observed. This reveals that the 
patch had a smooth &flat surface & the smooth surface could be maintained when the patch 
was applied to the skin.
In-vitro diffusion study of transdermal patch
              Table14: Results of in-vitro release study of transdermal patch
Time in hours %Cumulative drug release
0.5 6.7
1 10.83
2 17.25
3 21.9
4 25.76
5 34.03
6 45.29
Initial length(cm) Final length(cm) % Constriction % Flatness
Trial1 Trial2 Trial3 Avg Trial1 Trial2 Trial3 Avg
3 5 3 3.66 3 5 3 3.66 0 100
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Time in hours %Cumulative drug release
7 54.43
8 63.99
9 65.69
10 70.18
11 74.82
12 80.71
Figure19:In-vitro diffusion study of transdermal patch of optimised formulation
The in-vitro diffusion study of the transdermal patch incorporated with F12 was carried out 
using Franz diffusion cell with egg membrane as the semi-permeable membrane. The data 
obtained is given in table14 & plot was drawn between % cumulative drug release & time as 
shown in the above figure. The percentage cumulative release over a period of 12 hrs was 
found to be 80.71%.
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Release kinetics
Table15: Data for kinetic study
Sl.no Time(hrs) % CDR Log%CDR % 
cumulative 
drug 
remaining
Log % 
cumulative 
drug 
remaining
Log time Time
1/2
1 0.5 6.7 0.826 93.3 1.969 -0.30 0.707
2 1 10.83 1.034 89.17 1.950 0 1
3 2 17.25 1.236 82.75 1.917 0.301 1.414
4 3 21.9 1.340 78.1 1.892 0.477 1.732
5 4 25.76 1.410 74.24 1.870 0.602 2
6 5 34.03 1.531 65.97 1.819 0.698 2.236
7 6 45.29 1.656 54.71 1.738 0.778 2.449
8 7 54.43 1.735 45.57 1.658 0.845 2.645
9 8 63.99 1.806 36.01 1.556 0.903 2.828
10 9 65.69 1.817 34.31 1.535 0.954 3
11 10 70.18 1.846 29.82 1.474 1 3.162
12 11 74.82 1.874 25.18 1.401 1.041 3.316
13 12 80.71 1.907 19.2 1.283 1.079 3.464
In-vitro release data obtained for the trandermal patch containing optimised proniosome
formulation was subjected to kinetic analysis. The percentage cumulative release data 
obtained were fitted to zero order, first order, Higuchi square root of time & Korsmeyer –
Peppas equation to understand the mechanism of drug release from the proniosomal 
transdermal patch. The plots are shown below. From the regression values, it was concluded 
that the formulation followed zero order kinetics. The slope value (n) obtained from 
Korsmeyer- Peppas plot was 0.815, which indicates that the formulation followed non-
Fickian mechanism of drug release.
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Figure20: Zero order plot
Figure21: First order plot
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Figure22: Higuchi plot
Figure23: Korsmeyer-Peppas plot
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                         Table16: Result of kinetic data analysis
Formulation Zero
order
First 
order
Higuchi 
model
Korsmeyer-
Peppas model
F12 
proniosomal 
patch
R
2
R
2
R
2
n R
2
0.9806 0.8703 0.9588 0.815 0.9827
Stability study
Stability study for the most satisfactory formulation F12 after incorporating into transdermal
patch was carried out at accelerated temperature 40±2ºC and RH 75±5% for 45 days. After 
45 days the patch was evaluated for physical appearance, drug content &in-vitro release 
study. From the results obtained it was observe that there was no major change in various 
parameters at accelerated temperature. Thus it can be concluded that the formulation is stable 
at the specified temperature for a period of 45 days.
Table17:  Results of stability study
Sl.no Accelerated temp: 40±2ºC, Relative humidity: 75±5% RH
Parameters Initial 30
th 
day 45
th
day
1. Physical appearance Yellowish 
white colour
No change No change
2. Drug content 89.24%w/w 89.00%w/w 88.62%w/w
3. % Cumulative drug 
release
80.8% 80% 79.57%
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SUMMARY AND CONCLUSION
Aim
In the present study, an attempt was made to formulate proniosomes containing 
Metronidazole benzoate and incorporating it in transdermal patch for controlled and 
prolonged release of drug. The drug has low aqueous solubility, which can affect its 
dissolution leading to poor BA.  Incorporation into proniosomes can lead to reduced dose, 
improved bioavailability and prolonged release.  Further formulating in form of transdermal 
patch allows controlled release of the drug.
Formulation
Proniosomes were prepared using slurry method with different non- ionic surfactants and also 
in different surfactant: cholesterol ratios. Two formulations were prepared using different 
excepients. In one formulation lecithin was used as the membrane stabilizer and in another 
the carrier used was lactose .From the prepared proniosomal formulations , the best 
formulation which contained surfactant:cholesterol in the ratio 1:1and mannitol as the carrier
was selected based on various evaluation parameters and was incorporated into transdermal 
patch prepared using HPMC as the polymer. A total of 14 formulations were prepared.
UV spectrophotometric method was developed for determining Metronidazole benzoate in 
5% ethanol at 309nm. A regression coefficient value of 0.9977 was noticed.
Evaluation
∑ FT-IR spectra of pure drug and drug-excepient mixture confirmed that there were no 
major interactions. Hence they were compatible.
∑ The proniosomal formulations were subjected to studies like angle of repose, optical 
microscopy, drug content analysis, entrapment efficiency and in- vitro diffusion 
study.
∑ The optimized formulation (F12) was further subjected to studies like ex-vivo
permeation, rate of spontaneity, vesicle size analysis, antifungal study and SEM.
∑ The prepared patch was evaluated for physical appearance, thickness, folding 
endurance, %moisture loss, % moisture absorption, drug content, water vapour 
transmission rate, % flatness, in-vitro diffusion study.
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∑ Release kinetics data analysis revealed that the patch followed zero order kinetics 
with non-Fickian diffusion of drug.
∑ Stability studies were carried out at accelerated temperature 40±2ºC, 75±5 % RH for 
45 days. There were no significant changes in the physical appearance, drug content 
and in-vitro drug diffusion profile.
CONCLUSION
Introduction of proniosomes have initiated a new area in vesicular research in 
transdermal drug delivery. Different reports show a promising future of proniosomes 
in making the topical delivery of various agents more effective. It was confirmed that 
proniosomal transdermal patch of metronidazole benzoate showed a better diffusion 
as well as stability profile , hence providing an attractive carrier for prolonged and 
controlled topical delivery. In conclusion , the novel proniosomal formulation is a 
promising option for transdermal delivery of metronidazole benzoate in the treatment 
of various systemic as well as topical bacterial infections. Further studies using 
animal models will throw more light on the effectiveness of the formulation.
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